CSBR - チャンピオンズ・オンコロジ― （Champions Oncology Inc.） チャンピオンズ・オンコロジ―CSBRのチャート
CSBRの企業情報
| symbol | CSBR |
|---|---|
| 会社名 | Champions Oncology Inc. （チャンピオンズ・オンコロジ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Champions Oncology Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice along with the patient data and molecular information associated with the tumors are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company''s TumorBank. チャンピオンズ・オンコロジ―は米国のバイオ医薬品・サ―ビス企業。がん治療に対する薬剤と技術サ―ビスの開発と商品化に従事する。人間のがん腫瘍をマウスに移植し開発する「TumorGraft」テクロノジ―は、個別のがん患者に合う治療を提供。事業は、医師・患者向けと製薬・バイオ医薬品企業向けの2分野で構成。本社はニュ―ジャ―ジ―州。 Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. |
| 本社所在地 | One University Plaza Suite 307 Hackensack NJ 07601 USA |
| 代表者氏名 | Joel Ackerman ジョエルアッカーマン |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 410-369-0365 |
| 設立年月日 | 31199 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 92人 |
| url | www.championsoncology.com |
| nasdaq_url | https://www.nasdaq.com/symbol/csbr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 0.19500 |
| 終値（lastsale） | 13.54 |
| 時価総額（marketcap） | 151166544.68 |
| 時価総額 | 時価総額（百万ドル） 142.56990 |
| 売上高 | 売上高（百万ドル） 21.43200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 141.83890 |
| 当期純利益 | 当期純利益（百万ドル） -0.32000 |
| 決算概要 | 決算概要 BRIEF: For the three months ended 31 July 2018 Champions Oncology Inc revenues increased 24% to $6.2M. Net income totaled $482K vs. loss of $674K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Sales and marketing decrease of 24% to $518K (expense) General and administrative decrease of 13% to $1.1M (expense). |
CSBRのテクニカル分析
CSBRのニュース
Champions Oncology Trades At A Sufficient Discount To R&D Capacity (NASDAQ:CSBR) 2023/01/29 05:37:56 Seeking Alpha
CSBR runs a PDX bank. PDXs are mice models of human derived tumors.
CALA , NUWE and CORZ among mid-day movers 2022/12/15 17:42:38 Seeking Alpha
Gainers: Icosavax (ICVX) +62%.Core Scientific (CORZ) +36%.Kintara KTRA +27%.Mullen Automotive MULN +26%.Clearmind Medicine CMND +26%.Champions Oncology (CSBR) +24%.Neonode…
Champions Oncology, Inc. (CSBR) Q2 2023 Earnings Call Transcript 2022/12/14 01:54:06 Seeking Alpha
Champions Oncology, Inc. (NASDAQ:NASDAQ:CSBR) Q2 2023 Results Conference Call December 13, 2022 04:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call…
Champions Oncology Non-GAAP EPS of $0.01 misses by $0.01, revenue of $14.28M beats by $0.34M (NASDAQ:CSBR) 2022/12/13 21:43:14 Seeking Alpha
Champions Oncology press release (CSBR): Q2 Non-GAAP EPS of $0.01 misses by $0.01.Revenue of $14.28M (+21.1% Y/Y) beats by $0.34M.Adjusted EBITDA of $686,000Discovery…
Champions Oncology, Inc.: Champions Oncology Reports Record Quarterly Revenue of $14.3 Million 2022/12/13 21:02:00 Finanz Nachrichten
HACKENSACK, NJ / ACCESSWIRE / December 13, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-drive…
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday 2022/09/16 08:38:59 Benzinga
Gainers HeartBeam, Inc. (NASDAQ: BEAT ) shares jumped 85.6% to close at $2.32 on Thursday after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO. NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO ) rose 47.2% to close at $24.82 after the company announced Dong-A has licensed its global exclusive development rights of DA-1241 for type 2 diabetes and non-alcoholic fatty hepatitis and DA-1726 for obesity and non-alcoholic fatty hepatitis to NeuroBo. Nabriva Therapeutics plc (NASDAQ: NBRV ) climbed 39.4% to close at $0.2671 after the company announced it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective on September 16, 2022. ZW Data Action Technologies Inc. (NASDAQ: CNET ) gained 37.4% to close at $0.91. ZW Data Action Technologies reported planned acquisition of Henan Baodun. ZeroFox Holdings, Inc. (NASDAQ: ZFOX ) gained 32.7% to close at $7.76.
Champions Oncology, Inc. (CSBR) Q1 2023 Earnings Call Transcript 2022/09/09 20:41:05 Seeking Alpha
Champions Oncology, Inc. (NASDAQ:NASDAQ:CSBR) Q1 2023 Earnings Conference Call September 8, 2022, 04:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call…
Champions Oncology GAAP EPS of -$0.02 misses by $0.03, revenue of $13.7M beats by $0.51M 2022/09/08 20:18:16 Seeking Alpha
Champions Oncology press release (CSBR): Q1 GAAP EPS of -$0.02 misses by $0.03.Revenue of $13.7M (+21.2% Y/Y) beats by $0.51M.Adjusted EBITDA of $450,000.The Company ended the…
Champions Oncology Reports Record Quarterly Revenue of $13.7 Million 2022/09/08 20:00:00 Wallstreet:Online
HACKENSACK, NJ / ACCESSWIRE / September 8, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today …
Earnings Preview For Champions Oncology 2022/09/07 14:10:34 Benzinga
Champions Oncology (NASDAQ: CSBR ) is set to give its latest quarterly earnings report on Thursday, 2022-09-08. Here''s what investors need to know before the announcement. Analysts estimate that Champions Oncology will report an earnings per share (EPS) of $0.01. Champions Oncology bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
Champions Oncology Inc (NASDAQ:CSBR) is debt free 2021/12/14 16:29:47 FXDailyReport
Champions Oncology Inc (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, stock rose 3.23% (As The post Champions Oncology Inc (NASDAQ:CSBR) is debt free appeared first on FXDailyReport.Com .
Champions Oncology, Inc. (CSBR) Q2 2022 Earnings Call Transcript 2021/12/14 00:44:32 AlphaStreet
Champions Oncology, Inc. (NASDAQ: CSBR) Q2 2022 earnings call dated Dec. 13, 2021. Corporate Participants: Ronnie Morris — President & Chief Executive Officer David Miller — Chief Financial Officer Analysts: Matt Hewitt — Craig-Hallum — Analyst […] The post Champions Oncology, Inc. (CSBR) Q2 2022 Earnings Call Transcript first appeared on AlphaStreet .
Champions Oncology Inc.''s (CSBR) CEO Ronnie Morris on Q2 2022 Results - Earnings Call Transcript 2021/12/14 00:33:02 Seeking Alpha
Champions Oncology, Inc.: Champions Oncology Reports Record Quarterly Revenue of $11.8 Million 2021/12/13 21:32:00 FinanzNachrichten
Reported income from operations of $263,000HACKENSACK, NJ / ACCESSWIRE / December 13, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming…